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http://dx.doi.org/10.1016/j.chembiol.2013.12.002It took 14 years for genetic testing to
become accessible enough for Rick
and Cristy Spooner of Rancho Santa
Margarita, California, to find what was
causing Calyn, their oldest daughter, to
develop tremors and miss develop-
mental milestones in walking, talking,
and comprehension. Their second
daughter, Raelyn was born healthy.
But their third baby, Ryann, developed
the same symptoms as Calyn. The
only clue was an anomalous constella-
tion of cells in the two girls’ cerebellums
seen by MRI. Exome sequencing
showed that her daughters had a rare
recessive mutation in the NUBPL gene
causing a mitochondrial disease called‘‘The urgency comes from [the knowledge] that 50% of rare dis-
ease patients are children and 30%of themwill not celebrate their
fifth birthday.’’— Christina Waters, Ph.D.Complex 1 Deficiency. ‘‘Our nuclear
gene is mutated,’’ Christy Spooner
says. ‘‘It is very rare.’’ A doctor from
the Mayo Clinic told her that it is more
common to win the lottery twice than
for she and her husband to have that
same mutation. Spooner knows of only
four other families with the disease.
Could a Rising Tide LiftMore Boats?
Christy Spooner’s dilemma is common.
Only about 400 therapies currently exist
for the 7000 estimated rare and neglected
diseases. In the US, a disease is consid-
ered rare if it affects less than 200,000
people; in Europe, one out of 2000. In
aggregate, about 30,000 people in the
U.S. and perhaps 300,000 globally are
affected by a rare disease.
Books and movies have profiled
stories of parents such as John Crowley,
now CEO of Amicus Therapeutics, who
built Novazyme Pharmaceuticals from a
startup to cure his children of Pompe
Disease, and the struggle of the Hempel
family to get FDA to approve of an exper-imental therapy for their twins with Nie-
mann-Pick type C1, a neurodegenerative
disease. Patient groups are funding
research, registries, natural history and
biomarker studies and are collaborating
with academic researchers and com-
panies on clinical trials to advance
therapies. FasterCures, the venture phi-
lanthropy advisor started by former finan-
cier Michael Milken, now lists 51 consor-
tiums devoted to developing research,
therapies, standards, and biomarkers in
rare diseases.
According to Cristina Csimma, Ph.D.,
CEO of Cydan, a new for-profit acceler-
ator for rare diseases located in
Cambridge, Massachusetts, four factorsare intersecting for the first time: (1)
advances in science enabling more pre-
cise targeting of disease, (2) the develop-
ment of sophisticated and influential
disease foundations and patient advo-
cacy groups, (3) increased funding due
to the influx of the large pharma with sub-
stantial external R&D devoted to rare dis-
eases, and (4) a very favorable regulatory
environment that provides the opportu-
nities to engage the agencies at a very
early stage.
This climate has fostered proliferation
of biotechs focusing on rare and ultra
rare diseases: Genzyme, Amicus Thera-
peutics, BioMarin, Ultragenyx, Synageva,
and Shire are among the dozens of
companies. Due to orphan drug legisla-
tion and current reimbursement policies,
a company can command a high price
for a rare disease drug that fills an
unmet need.
A Special Breed of Sheep
Because of the sheer number of dis-
eases and the difficulty of the scienceChemistry & Biology 20, December 19, 2013involved, even the most established
rare disease organizations still struggle
for answers. The National Tay-Sachs &
Allied Diseases Association (NTSAD) is
56 years old. Children who are born
with Tay-Sachs inevitably deteriorate
and die, generally before the age of
five. Due to carrier screening programs
in high-risk populations such as Ashke-
nazi Jews, the incidence of Tay-Sachs
has declined, but anybody can be a
carrier, according to Sue Kahn, execu-
tive director of the NTSAD. Hence, the
Delaware Valley Chapter of the NTSAD
is currently conducting studies among
Americans of Irish ancestry.
According to Kahn, in the last decade
the NTSAD has awarded almost $3
million in research grants and is currently
focusing on the Tay-Sachs Gene Ther-
apy Consortium, which is comprised of
researchers from Massachusetts Gen-
eral Hospital; the University of Massa-
chusetts Medical Center, Worcester;
Auburn University, Boston College; and
Cambridge University (U.K.). The Con-
sortium’s preclinical work showed
encouraging results in animal models, in
particular in Jacobs Sheep, a type of
heritage sheep, which are natural carriers
of Tay-Sachs (the disease also has been
found in Muntjak deer, and American
flamingos). Funded by a $3.5 million
milestone grant from the NIH, the Con-
sortium has collected natural history
studies and is refining vectors to get to
human trials within a year or two.
‘‘Rare diseases are a not an easy prob-
lem to solve,’’ says Kahn.
RARE Science Looks for New
Pathways
New rare disease accelerators may help
speed the trajectory of certain therapies
to patients. ‘‘The drug development path
traditionally is focused on one drug–one
disease,’’ says Christina Waters, Ph.D.,
founder and CEO of RARE Science,
a San Diego-based nonprofit research
accelerator of therapies for rare diseases.ª2013 Elsevier Ltd All rights reserved 1435
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diseases, and using targeted methods
like gene therapy, but there is a need
for integrated ‘omics’ platforms and a
change in thinking to focus on the under-
lying biology of disease to expand use
of therapies and make it practical to use
drugs across diseases of similar biology.’’
Launched in September 2013, RARE Sci-
ence is a consortium of researchers from
Sanford-Burnham Medical Research
Institute; University of California, San
Diego; University of California, San Fran-
cisco; the Salk Institute; and the Feinberg
School of Medicine of Northwestern
University. RARE Science board mem-
ber Dr. David Parkinson is a partner at
the venture capital firm New Enterprise
Associates (NEA) and CEO of Mary-
land-based Zyngenia, a preclinical com-
pany developing single-molecule bio-
therapeutics that use multiple pathways
simultaneously to treat multifactorial
diseases.
The Tay-Sachs genetic mutation re-
sults in the insufficient activity of a crucial
enzyme, and although there is no cure at
this time, in the future this could be
addressed with gene therapy. The inade-
quate enzyme activity also results in
many identifiable phenotypes or symp-
toms such as seizures, which can poten-
tially be treatable with small-molecule
therapies. These drugs do not replace
the missing enzyme activity in Tay-
Sachs, but, according to Waters, devel-
oping a better understanding of the mo-
lecular pathways involved could support
using new combinations of currently
approved therapies that could aid in
managing the disease phenotypes.
The RARE Science computational
platform categorizes diseases according
to phenotypes/molecular pathways and
can detect shared biology between
disparate conditions. It integrates various
‘‘omics’’ methodologies; genomics, tran-
scriptomics, metabolomics, proteomics,
and links to mechanisms of approved
therapeutics to ‘‘reposition’’ approved
drugs. According to Waters, the RARE
Science computational platform lends
itself to working with rare variants and
the mutations driving Mendelian inherited
diseases. This involves identifying patient
subpopulations, linking their genetic sig-
natures and the resulting biology to a
companion therapeutic, and understand-
ing what it takes to get an FDA-approved1436 Chemistry & Biology 20, December 19,drug validated and approved for addi-
tional disease indications.
‘‘The urgency comes from [the knowl-
edge] that 50% of rare disease patients
are children and 30% of them will
not celebrate their fifth birthday,’’ says
Waters. ‘‘They can’t wait for a drug dis-
covery program. We really need to find
immediate therapeutic solutions in addi-
tion to improved diagnostics.’’
RARE Science collaborates with the
Global Genes Project, an Aliso Viejo, Cal-
ifornia, umbrella patient organization. The
next steps are to build networks with
childrens’ hospitals as well as disease-
focused foundations and to get projects
commissioned and funded in specific dis-
ease areas.
This model is already being used
commercially by NuMedii, a Palo Alto,
California, based startup cofounded by
Stanford professor Dr. Atul Butte and
his wife, Dr. Gini Deshpande. Butte,
Deshpande, and their colleagues use
’’Big Data’’ computing to sift through
troves of public data and develop pre-
dictive algorithms to detect gene expres-
sion profiles in diseases, contrasting and
comparing them to those of approved
drugs that can activate or block mo-
lecular pathways. NuMedii ‘‘de-risks’’
drug candidates and partners with
pharma companies for development.
The company is funded by Claremont
Creek Ventures and Lightspeed Venture
Partners.
Cydan Goes Drug Hunting
David Mott, general partner at NEA, re-
calls a conversation he had at a confer-
ence 5 years ago with Dr. Eric Topol,
director of the Scripps Translational Sci-
ence Institute. Topol described how ge-
nomics advances were already making it
possible to chop up big diseases into
smaller ones. What if they could create
an accelerator staffed with experienced
drug developers who could perform
fast validation of projects—or fast kill?
Mott launched Cydan in April 2013 with
$16 million from NEA, Pfizer Venture
Investments, and Alexandria Venture In-
vestments. In October 2013, Lundbeck-
fond Ventures, and Bay City Capital led
an additional $10 million financing round
with the prior investors.
‘‘The way science has evolved, we are
beginning to understand these diseases
at a genetic and molecular level,’’ says2013 ª2013 Elsevier Ltd All rights reservedMott. ‘‘We are trying to stop disease at
its beginning. It is decreasing our ex-
penses in drug development. It is chang-
ing its expense-to-risk ratio.’’
According to Mott, segmenting disease
into separate subtypes is already being
done in cancer, as with, for example,
Crizotinib, an ALK inhibitor for non-small
cell lung cancer that the FDA approved
in 2011. ‘‘Lung cancer is not a single can-
cer but many different types of cancers
that affect the lung,’’ says Mott. ‘‘There
is a big crossover between rare genetic
disease and targeted therapeutics in
oncology.’’
Cydan will screen potential candidates
from academic labs and patient foun-
dations in the US and globally. Accord-
ing to Mott, once a compound is
selected and passes a 12 month ‘‘de-
risking’’ program, the money is already
raised and a management team is in
place, saving perhaps 6–12 months
of downtime that would otherwise be
spent in fundraising and setting up a
startup infrastructure. The accelerator
focuses on the crack between academic
research and getting a company staffed
and funded. ‘‘I think that crack is a very
fruitful place to go drug hunting,’’ says
Mott.
‘‘Patient foundations are very interested
in Cydan’s model because we can ask
key development questions that can
enable rigorous go/no go decisions—
and have capital on the table,’’ says
Csimma. ‘‘They like the fact that we
come to the table with a very objective
approach because we are not asset
centric.’’ Cydan looks for ‘‘assets’’ with
well-characterized genetic etiology, usu-
ally animal data, or even clinical data
in a different indication. Assets would
also be backed up by global registries
and natural history studies from patient
foundations. Assets must provide mean-
ingful clinical benefit for an unmet
need and potential for an eventual
spinout and/or expanded indications.
Successful candidates can then transi-
tion smoothly to series A-supported
development programs. The accelerator
plans to launch up to five companies
in 4 years. Cydan will also introduce
early stage investors and academics or
foundations.
A year after their daughters’ diagnosis,
the Spooners continue to work with doc-
tors, including Dr. Virginia Kimonis in the
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the University of California, Irvine, to
research possible trial drugs. They are
considering fundraising to support
research opportunities. They are also
workingwith the UMDF (UnitedMitochon-drial Foundation) to stay informed about
any drugs or therapies that become avail-
able for their disease and/or to treat
similar symptoms. ‘‘We are not sure if
our disease is progressive, so we are
very concerned and needing to stayChemistry & Biology 20, December 19, 2013aware and open for treatments and hope-
fully one day a cure.’’ writes Christy
Spooner.Wendy Wolfson (wendywolfson@nasw.org) is a
science writer based in Southern California.ª2013 Elsevier Ltd All rights reserved 1437
